argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

argenx announced that Phase 3 ALKIVIA study results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026. The study met its primary endpoint, showing a 15.4-point greater improvement in Total Improvement Score versus placebo at Week 52 in the combined IMNM and DM population, with improvements observed as early as Week 4 and sustained through 52 weeks. The drug was well-tolerated with a consistent safety profile.

10/19/2026, 8:00 AM • GlobeNewswire

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

argenx announced it will host a conference call on October 22, 2026 at 2:30 PM CET to discuss third quarter 2026 financial results and provide a business update. The immunology company will present via webcast and phone with dial-in numbers provided for multiple countries.

10/15/2026, 1:00 AM • GlobeNewswire

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.

10/05/2026, 4:26 AM • The Motley Fool

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

argenx presented new clinical data at the AANEM and MGFA scientific sessions demonstrating deepening improvements in ocular myasthenia gravis (MG) with VYVGART, sustained one-year efficacy in anti-AChR antibody-negative MG patients, and benefits of earlier treatment initiation. Real-world evidence from over 1,100 U.S. MG patients showed greater clinical gains when treatment started within one year of diagnosis. Long-term CIDP data reinforced consistent safety and efficacy, with a Phase 4 study supporting direct transition from IVIg. Pipeline candidates empasiprubart and adimanebart showed promising Phase 2 results in multifocal motor neuropathy and congenital myasthenic syndrome respectively.

09/29/2026, 8:00 AM • GlobeNewswire

argenx Completes Acquisition of Forte Biosciences, Inc.

argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

08/27/2026, 8:50 AM • GlobeNewswire

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.

08/06/2026, 7:48 AM • GlobeNewswire

argenx to Host Autoimmune Myositis R&D Webinar

argenx will host a webinar on June 23, 2026, to discuss advancing FcRn leadership into autoimmune myositis. The company will present data on efgartigimod showing sustained patient benefits in myositis and Sjogren's disease, with management and external key opinion leaders from leading medical institutions participating.

06/23/2026, 1:00 AM • GlobeNewswire

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

06/11/2026, 9:09 AM • Benzinga

argenx to Present at Upcoming Investor Conferences

argenx announced that its management team will participate in two major investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference on June 3 in Chicago and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami. Live webcasts will be available on the company's investor website.

05/27/2026, 1:00 AM • GlobeNewswire

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

05/18/2026, 1:00 PM • GlobeNewswire

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

The FDA approved a label expansion for Argenx's VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo to treat all serotypes of adult patients with generalized myasthenia gravis (gMG), including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients. The approval expands the addressable market by 18% and positions the franchise to exceed $5 billion in annual sales with 64% year-over-year growth. ARGX shares rose 2.33% following the announcement.

05/11/2026, 1:37 PM • Benzinga

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

The FDA has expanded approval of VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) to treat all serotypes of adult patients with generalized myasthenia gravis, including seronegative patients who previously had limited treatment options. The approval is based on the Phase 3 ADAPT SERON study, which demonstrated clinically meaningful improvements in patient daily living activities with a consistent safety profile.

05/08/2026, 6:27 PM • GlobeNewswire

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx, a global immunology company, announced it will host a conference call on May 7, 2026 at 2:30 PM CET to discuss its first quarter 2026 financial results and provide a business update. The company is committed to developing novel antibody-based medicines for severe autoimmune diseases.

04/30/2026, 1:00 AM • GlobeNewswire

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx announced positive Phase 3 trial results for VYVGART across multiple myasthenia gravis (MG) subtypes and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 AAN Annual Meeting. ADAPT OCULUS demonstrated VYVGART as the first targeted biologic treatment for ocular MG, while ADAPT SERON showed efficacy across seronegative MG patients. ADHERE analysis supported earlier use of VYVGART Hytrulo in treatment-naïve CIDP patients with 87.5% achieving early benefit. The company also presented Phase 3 trial designs for empasiprubart in CIDP and follow-up data for adimanebart in congenital myasthenic syndromes.

04/18/2026, 1:00 AM • GlobeNewswire

Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP

Folia Health announced a collaboration with argenx to launch a first-of-its-kind at-home observational real-world evidence initiative for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study uses Folia's home-reported outcomes platform to capture symptom severity, treatment utilization, and daily disease management directly from patients and caregivers over a six-month period.

04/07/2026, 10:00 AM • GlobeNewswire